{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:28:14Z","timestamp":1792787294608,"version":"4.5.0"},"reference-count":66,"publisher":"BMJ","issue":"10","license":[{"start":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T00:00:00Z","timestamp":1759795200000},"content-version":"unspecified","delay-in-days":6,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"National Natural Science Foundation project","award":["82272811"],"award-info":[{"award-number":["82272811"]}]},{"name":"Jiangsu Provincial Medical Key Discipline","award":["ZDXK202233"],"award-info":[{"award-number":["ZDXK202233"]}]},{"name":"Social Development Project of Jiangsu Province","award":["BE2023654"],"award-info":[{"award-number":["BE2023654"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2025,9,21]]},"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Cytokine-induced memory-like natural killer (CIML NK) cells demonstrate potent antitumor efficacy against hematological malignancies. Nevertheless, the therapeutic potential of adoptive NK cell transfer remains constrained in solid tumors due to insufficient tumor infiltration efficiency. Developing a novel tetravalent bispecific killer engager (BiKE) to modify CIML NK cells would be a promising strategy to enhance therapeutic efficacy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We employed SpyTag-SpyCatcher technology to engineer tetravalent BiKEs, specifically KK-LC-1\u00d7CD16A, and to equip CIML NK cells with this protein. Flow cytometry and a luciferase reporter gene system were used to evaluate the activation and cytotoxicity of CIML NK cells. Histological analysis and in vivo real-time fluorescence imaging were employed in the xenograft tumor model to confirm the tumor-infiltrating effectiveness of KK-LC-1\u00d7CD16A-armed CIML NK cells. The in vivo antitumor efficacy of armed CIML NK cells was evaluated in subcutaneous gastric cancer xenograft models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We successfully developed a tetravalent NK cell engager, KK-LC-1\u00d7CD16A, which exhibits excellent binding affinity to its targets. CIML NK cells armed with this protein exhibit enhanced activation and augmented cytotoxicity against tumor cells. In xenograft tumor models, the accumulation of KK-LC-1\u00d7CD16A-armed CIML NK cells at the tumor site was significantly increased, resulting in marked suppression of tumor growth and prolonged survival in mice.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>KK-LC-1\u00d7CD16A-armed CIML NK cells demonstrate significant clinical potential as a multifunctional therapeutic platform, effectively overcoming both tumor infiltration limitations and functional suppression in conventional NK cell therapies. This approach provides valuable insights for optimizing the therapeutic efficacy of CIML NK cell therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jitc-2025-012504","type":"journal-article","created":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T09:35:21Z","timestamp":1759916121000},"page":"e012504","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Novel tetrameric bispecific KK-LC-1\u00d7CD16A-armed memory-like NK cells enhance antitumor efficacy in gastric cancer"],"prefix":"10.1136","volume":"13","author":[{"given":"Mengzhu","family":"Li","sequence":"first","affiliation":[{"name":"Department of Oncology, Nanjing Drum Tower Hospital and Group's Suqian Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, Jiangsu, China"},{"name":"Department of Oncology, China Pharmaceutical University Nanjing Drum Tower Hospital, Nanjing, Jiangsu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianran","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Oncology, Nanjing Drum Tower Hospital and Group's Suqian Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, Jiangsu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siwen","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Oncology, Nanjing Drum Tower Hospital and Group's Suqian Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, Jiangsu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxiang","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Oncology, Nanjing Drum Tower Hospital and Group's Suqian Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, Jiangsu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9839-8480","authenticated-orcid":false,"given":"Qin","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Oncology, Nanjing Drum Tower Hospital and Group's Suqian Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, Jiangsu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Oncology, Nanjing Drum Tower Hospital and Group's Suqian Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, Jiangsu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingyi","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Oncology, Nanjing Drum Tower Hospital and Group's Suqian Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, Jiangsu, China"},{"name":"Department of Oncology, China Pharmaceutical University Nanjing Drum Tower Hospital, Nanjing, Jiangsu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lanqi","family":"Cen","sequence":"additional","affiliation":[{"name":"Department of Oncology, Nanjing Drum Tower Hospital and Group's Suqian Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, Jiangsu, China"},{"name":"Department of Oncology, China Pharmaceutical University Nanjing Drum Tower Hospital, Nanjing, Jiangsu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Zou","sequence":"additional","affiliation":[{"name":"Department of Oncology, Nanjing Drum Tower Hospital and Group's Suqian Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, Jiangsu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manman","family":"Tian","sequence":"additional","affiliation":[{"name":"Department of Oncology, Nanjing Drum Tower Hospital and Group's Suqian Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, Jiangsu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5673-1783","authenticated-orcid":false,"given":"Wenxiu","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Oncology, Nanjing Drum Tower Hospital and Group's Suqian Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, Jiangsu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4800-6156","authenticated-orcid":false,"given":"Rutian","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Oncology, Nanjing Drum Tower Hospital and Group's Suqian Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, Jiangsu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3157-4640","authenticated-orcid":false,"given":"Jie","family":"Shen","sequence":"additional","affiliation":[{"name":"Department of Oncology, Nanjing Drum Tower Hospital and Group's Suqian Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, Jiangsu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2539-7732","authenticated-orcid":false,"given":"Baorui","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Oncology, Nanjing Drum Tower Hospital and Group's Suqian Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, Jiangsu, China"},{"name":"Department of Oncology, China Pharmaceutical University Nanjing Drum Tower Hospital, Nanjing, Jiangsu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1222-0505","authenticated-orcid":false,"given":"Jie","family":"Shao","sequence":"additional","affiliation":[{"name":"Department of Oncology, Nanjing Drum Tower Hospital and Group's Suqian Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, Jiangsu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,10,8]]},"reference":[{"key":"2025111301351351000_13.10.e012504.1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31288-5"},{"key":"2025111301351351000_13.10.e012504.2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21763"},{"key":"2025111301351351000_13.10.e012504.3","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2015.1069936","article-title":"Gastric cancer cells inhibit natural killer cell proliferation and induce apoptosis via prostaglandin E2","volume":"5","author":"Li","year":"2016","journal-title":"Oncoimmunology"},{"key":"2025111301351351000_13.10.e012504.4","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/s41388-020-01561-z","article-title":"The role of natural killer cell in gastrointestinal cancer: killer or helper","volume":"40","author":"Wang","year":"2021","journal-title":"Oncogene"},{"key":"2025111301351351000_13.10.e012504.5","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1186\/s13287-021-02655-5","article-title":"Cytokine-induced memory-like natural killer cells for cancer immunotherapy","volume":"12","author":"Tarannum","year":"2021","journal-title":"Stem Cell Res Ther"},{"key":"2025111301351351000_13.10.e012504.6","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaf2341","article-title":"Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia","volume":"8","author":"Romee","year":"2016","journal-title":"Sci Transl Med"},{"key":"2025111301351351000_13.10.e012504.7","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-0851"},{"key":"2025111301351351000_13.10.e012504.8","doi-asserted-by":"crossref","first-page":"114617","DOI":"10.1016\/j.ejmech.2022.114617","article-title":"An auristatin-based peptide-drug conjugate targeting Kita-Kyushu lung cancer antigen 1 for precision chemoradiotherapy in gastric cancer","volume":"241","author":"Chen","year":"2022","journal-title":"Eur J Med Chem"},{"key":"2025111301351351000_13.10.e012504.9","doi-asserted-by":"crossref","first-page":"115718","DOI":"10.1016\/j.biopha.2023.115718","article-title":"Cytokine\u2010Induced Memory\u2010Like NK Cells: Emerging strategy for AML immunotherapy","volume":"168","author":"Bakhtiyaridovvombaygi","year":"2023","journal-title":"Biomed Pharmacother"},{"key":"2025111301351351000_13.10.e012504.10","doi-asserted-by":"crossref","first-page":"728","DOI":"10.4161\/mabs.28591","article-title":"A novel tetravalent bispecific TandAb (CD30\/CD16A) efficiently recruits NK cells for the lysis of CD30+ tumor cells","volume":"6","author":"Reusch","year":"2014","journal-title":"MAbs"},{"key":"2025111301351351000_13.10.e012504.11","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-17-0550"},{"key":"2025111301351351000_13.10.e012504.12","doi-asserted-by":"crossref","DOI":"10.3390\/antib11010012","article-title":"Cryopreservation of Natural Killer Cells Pre-Complexed with Innate Cell Engagers","volume":"11","author":"Reusch","year":"2022","journal-title":"Antibodies (Basel)"},{"key":"2025111301351351000_13.10.e012504.13","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-009070","article-title":"Generation of non-genetically modified, CAR-like, NK cells","volume":"12","author":"Co\u00ebnon","year":"2024","journal-title":"J Immunother Cancer"},{"key":"2025111301351351000_13.10.e012504.14","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1021\/acscentsci.8b00552","article-title":"A Single-Step Chemoenzymatic Reaction for the Construction of Antibody\u2013Cell Conjugates","volume":"4","author":"Li","year":"2018","journal-title":"ACS Cent Sci"},{"key":"2025111301351351000_13.10.e012504.15","doi-asserted-by":"publisher","DOI":"10.1021\/acschembio.1c00022"},{"key":"2025111301351351000_13.10.e012504.16","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13112724","article-title":"A Novel off-the-Shelf Trastuzumab-Armed NK Cell Therapy (ACE1702) Using Antibody-Cell-Conjugation Technology","volume":"13","author":"Li","year":"2021","journal-title":"Cancers (Basel)"},{"key":"2025111301351351000_13.10.e012504.17","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jcyt.2020.01.003","article-title":"A novel antibody-cell conjugation method to enhance and characterize cytokine-induced killer cells","volume":"22","author":"Frank","year":"2020","journal-title":"Cytotherapy"},{"key":"2025111301351351000_13.10.e012504.18","doi-asserted-by":"crossref","DOI":"10.1002\/mco2.553","article-title":"iPSC\u2010derived NK cells with site\u2010specific integration of CAR19 and IL24 at the multi\u2010copy rDNA locus enhanced antitumor activity and proliferation","volume":"5","author":"Zhang","year":"2024","journal-title":"MedComm"},{"key":"2025111301351351000_13.10.e012504.19","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2022.2054105","article-title":"STING agonist cGAMP enhances anti-tumor activity of CAR-NK cells against pancreatic cancer","volume":"11","author":"Da","year":"2022","journal-title":"Oncoimmunology"},{"key":"2025111301351351000_13.10.e012504.20","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24109038","article-title":"Next Generation CD44v6-Specific CAR-NK Cells Effective against Triple Negative Breast Cancer","volume":"24","author":"Raftery","year":"2023","journal-title":"Int J Mol Sci"},{"key":"2025111301351351000_13.10.e012504.21","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1145706","article-title":"Anti-tumor efficacy of anti-GD2 CAR NK-92 cells in diffuse intrinsic pontine gliomas","volume":"14","author":"Zuo","year":"2023","journal-title":"Front Immunol"},{"key":"2025111301351351000_13.10.e012504.22","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-0164"},{"key":"2025111301351351000_13.10.e012504.23","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1038\/s41591-025-03640-8","article-title":"Allogeneic NK cells with a bispecific innate cell engager in refractory relapsed lymphoma: a phase 1 trial","volume":"31","author":"Nieto","year":"2025","journal-title":"Nat Med"},{"key":"2025111301351351000_13.10.e012504.24","doi-asserted-by":"publisher","DOI":"10.1006\/jmbi.2000.4265"},{"key":"2025111301351351000_13.10.e012504.25","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.ymeth.2018.09.010","article-title":"Bispecific applications of non-immunoglobulin scaffold binders","volume":"154","author":"Hober","year":"2019","journal-title":"Methods"},{"key":"2025111301351351000_13.10.e012504.26","first-page":"423","article-title":"Beyond Antibodies: The DARPin(\u00ae)","volume":"34","author":"Stumpp","year":"2020","journal-title":"Drug Platform BioDrugs"},{"key":"2025111301351351000_13.10.e012504.27","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2008.04.013"},{"key":"2025111301351351000_13.10.e012504.28","doi-asserted-by":"crossref","first-page":"7889","DOI":"10.1038\/s41467-025-63269-6","article-title":"Mesothelin-directed protein-drug conjugates for mesothelin-low solid tumor therapy","volume":"16","author":"Wang","year":"2025","journal-title":"Nat Commun"},{"key":"2025111301351351000_13.10.e012504.29","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.121.262542"},{"key":"2025111301351351000_13.10.e012504.30","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-23-0692"},{"key":"2025111301351351000_13.10.e012504.31","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1002\/jha2.968","article-title":"A phase 1b\/2 study evaluating efficacy and safety of MP0250, a designed ankyrin repeat protein (DARPin) simultaneously targeting vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF), in combination with bortezomib and dexamethasone, in patients with relapsed or refractory multiple myeloma","volume":"5","author":"Knop","year":"2024","journal-title":"EJHaem"},{"key":"2025111301351351000_13.10.e012504.32","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/s44321-024-00184-1","article-title":"A therapeutic regimen using neoantigen-specific TCR-T cells for HLA-A*2402-positive solid tumors","volume":"17","author":"Bei","year":"2025","journal-title":"EMBO Mol Med"},{"key":"2025111301351351000_13.10.e012504.33","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1097\/QAI.0000000000003518","article-title":"HIV-1 Elite Controllers Are Characterized by Elevated Levels of CD69-Expressing Natural Killer Cells","volume":"97","author":"Batohi","year":"1999","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2025111301351351000_13.10.e012504.34","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V106.11.3322.3322","article-title":"CD69 Is Required for Activated NK Cell-Mediated Killing of Resistant Targets","volume":"106","author":"Marden","year":"2005","journal-title":"Blood"},{"key":"2025111301351351000_13.10.e012504.35","doi-asserted-by":"publisher","DOI":"10.1016\/j.cytogfr.2006.07.003"},{"key":"2025111301351351000_13.10.e012504.36","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2014.01.006"},{"key":"2025111301351351000_13.10.e012504.37","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1801137"},{"key":"2025111301351351000_13.10.e012504.38","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-06-741041"},{"key":"2025111301351351000_13.10.e012504.39","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.169.8.4230"},{"key":"2025111301351351000_13.10.e012504.40","doi-asserted-by":"publisher","DOI":"10.1007\/BF01540972"},{"key":"2025111301351351000_13.10.e012504.41","doi-asserted-by":"publisher","DOI":"10.1189\/jlb.0611308"},{"key":"2025111301351351000_13.10.e012504.42","doi-asserted-by":"crossref","DOI":"10.1186\/s12935-014-0100-1","article-title":"Increase of IFN-\u03b3 and TNF-\u03b1 production in CD107a + NK-92 cells co-cultured with cervical cancer cell lines pre-treated with the HO-1 inhibitor","volume":"14","author":"G\u00f3mez-Lomel\u00ed","year":"2014","journal-title":"Cancer Cell Int"},{"key":"2025111301351351000_13.10.e012504.43","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellimm.2008.08.007"},{"key":"2025111301351351000_13.10.e012504.44","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-08-453738"},{"key":"2025111301351351000_13.10.e012504.45","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021013972"},{"key":"2025111301351351000_13.10.e012504.46","doi-asserted-by":"crossref","DOI":"10.1172\/JCI154334","article-title":"Expansion, persistence, and efficacy of donor memory-like NK cells infused for posttransplant relapse","volume":"132","author":"Shapiro","year":"2022","journal-title":"J Clin Invest"},{"key":"2025111301351351000_13.10.e012504.47","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000131","article-title":"CCL5-armed oncolytic virus augments CCR5-engineered NK cell infiltration and antitumor efficiency","volume":"8","author":"Li","year":"2020","journal-title":"J Immunother Cancer"},{"key":"2025111301351351000_13.10.e012504.48","doi-asserted-by":"publisher","DOI":"10.21873\/invivo.11307"},{"key":"2025111301351351000_13.10.e012504.49","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-16-0152"},{"key":"2025111301351351000_13.10.e012504.50","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s13045-015-0188-3","article-title":"AFM13: a first-in-class tetravalent bispecific anti-CD30\/CD16A antibody for NK cell-mediated immunotherapy","volume":"8","author":"Wu","year":"2015","journal-title":"J Hematol Oncol"},{"key":"2025111301351351000_13.10.e012504.51","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-04-419283"},{"key":"2025111301351351000_13.10.e012504.52","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20120944"},{"key":"2025111301351351000_13.10.e012504.53","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2019.01.006"},{"key":"2025111301351351000_13.10.e012504.54","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-11-2544"},{"key":"2025111301351351000_13.10.e012504.55","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-10-2173"},{"key":"2025111301351351000_13.10.e012504.56","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-3847"},{"key":"2025111301351351000_13.10.e012504.57","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-024-01145-x"},{"key":"2025111301351351000_13.10.e012504.58","doi-asserted-by":"crossref","DOI":"10.1007\/s00262-024-03795-2","article-title":"NKG2D-bispecific enhances NK and CD8+ T cell antitumor immunity","volume":"73","author":"Herault","year":"2024","journal-title":"Cancer Immunol Immunother"},{"key":"2025111301351351000_13.10.e012504.59","doi-asserted-by":"publisher","DOI":"10.1007\/s40291-021-00550-6"},{"key":"2025111301351351000_13.10.e012504.60","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1038\/s41423-024-01207-0","article-title":"CAR-T and CAR-NK as cellular cancer immunotherapy for solid tumors","volume":"21","author":"Peng","year":"2024","journal-title":"Cell Mol Immunol"},{"key":"2025111301351351000_13.10.e012504.61","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1384039","article-title":"Chimeric antigen receptor-natural killer cell therapy: current advancements and strategies to overcome challenges","volume":"15","author":"Kong","year":"2024","journal-title":"Front Immunol"},{"key":"2025111301351351000_13.10.e012504.62","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2013.14"},{"key":"2025111301351351000_13.10.e012504.63","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1002\/1097-0142(19851215)56:12<2799::AID-CNCR2820561215>3.0.CO;2-W","article-title":"Natural killer cell activity during the course of disease in patients with Hodgkin\u2019s disease","volume":"56","author":"Frydecka","year":"1985","journal-title":"Cancer"},{"key":"2025111301351351000_13.10.e012504.64","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.00267","article-title":"Acquired Natural Killer Cell Dysfunction in the Tumor Microenvironment of Classic Hodgkin Lymphoma","volume":"9","author":"Chiu","year":"2018","journal-title":"Front Immunol"},{"key":"2025111301351351000_13.10.e012504.65","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-018-0132-0"},{"key":"2025111301351351000_13.10.e012504.66","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15102712","article-title":"TIGIT Expression on Activated NK Cells Correlates with Greater Anti-Tumor Activity but Promotes Functional Decline upon Lung Cancer Exposure: Implications for Adoptive Cell Therapy and TIGIT-Targeted Therapies","volume":"15","author":"Hasan","year":"2023","journal-title":"Cancers (Basel)"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2025-012504","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T09:35:29Z","timestamp":1763026529000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2025-012504"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":66,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,10,8]]},"published-print":{"date-parts":[[2025,10]]}},"alternative-id":["10.1136\/jitc-2025-012504"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2025-012504","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10]]}}}